Areté
← All peptides
Melanocortin agonist (pigment / photoprotection)clinical

Melanotan-1

Melanotan-1 (afamelanotide)

The tanning peptide that actually has clinical data behind it — but almost nobody buying "melanotan" is taking this one. Melanotan-1 is the MC1R-selective α-MSH analogue: it darkens skin by driving real melanin, with none of the libido or appetite effects people associate with the name. The catch is that most "melanotan" sold and discussed online is its messier cousin, MT-2.

Area
Sexual & pigment
Class
Melanocortin agonist (pigment / photoprotection)
Standard dose
A 16 mg controlled-release SubQ implant every ~60 days — the regulated EPP product, not what the community injects
Evidence
clinical

What it is

People run it for one thing: a tan that comes from inside the skin rather than the sun, plus the photoprotection that comes with it. It pushes the skin to produce eumelanin, so users report tanning faster and burning less for the same sun exposure. As a regulated drug it's used for a rare light-sensitivity disease (erythropoietic protoporphyria, EPP) — the community tanning use borrows that biology off-label.

The single most useful thing to understand about this peptide is that it is NOT the one most people mean. Melanotan-1 is MC1R-selective — it hits the pigment receptor and essentially nothing else. Melanotan-2 is non-selective and also lights up MC3R and MC4R, which is where the libido, spontaneous-erection and appetite-suppression effects come from. So if a "tanning peptide" is giving someone those effects, they're on MT-2, not MT-1. The community signal is consistent on this: MT-1 users report the tan without the nausea-and-arousal rollercoaster, at the cost of MT-1 being slower and milder.

Mechanism

A linear, MC1R-selective analogue of α-melanocyte-stimulating hormone ([Nle4-D-Phe7]-α-MSH). Activating MC1R on melanocytes shifts pigment production toward eumelanin — the dark, photoprotective form — which is what increases tanning and raises the threshold for phototoxic/burn reactions. Because it is selective for MC1R and does not meaningfully engage MC3R/MC4R, it lacks the central libido and appetite actions that define MT-2.

How it works · scroll to follow the storyMC1R only
melanocyte · skin cellMC1RMC3RMC4RMT-1 · this oneMT-2 · usually soldtan · burn lessMT-2: nausea · appetite · libidohigh dose → moles darken · get checked

Step 1 · the mix-up

Most melanotan is not this one.

Two peptides share the name. The one people usually buy is the messy, non-selective cousin. This is the clean, selective one — and the difference is the whole point.

Step 2 · one receptor

Melanotan-1 hits a single target.

It is selective for MC1R — the pigment receptor on your skin's melanocytes — and essentially nothing else.

Step 3 · real pigment

It tells skin to make eumelanin.

Activating MC1R shifts pigment production toward eumelanin — the dark, protective kind — so you tan from the inside and burn less for the same sun.

Step 4 · the contrast

Its cousin lights up two more switches.

Melanotan-2 also hits MC3R and MC4R — where the nausea, appetite-loss and arousal effects come from. MT-1 leaves those switches alone. That is why it is the calmer one.

Step 5 · the real caution

More is not better — it is darker moles.

The dose-dependent downside is not a high — it is your existing moles and freckles darkening and enlarging, which can mask what a dermatologist watches for. Start low, get skin-checked.

The result

A tan from one clean switch.

Pigment and photoprotection from a single receptor — slower and milder than its cousin, but without the rollercoaster.

Real Phase-III data — but for a rare light-sensitivity disease as an implant, not for cosmetic tanning. And most melanotan sold online is the non-selective cousin, MT-2 — not this one.

Standard dose

Approved formA 16 mg controlled-release SubQ implant every ~60 days — the regulated EPP product, not what the community injectsclinical
Community starting dose~250–300 mcg SubQ to begin; the goal is to limit mole/freckle darkening, not to tan fast (proposed — pending dosing review)community
TitrationStep up ~250–300 mcg per week over the first weeks while watching the skincommunity
MaintenanceCommonly ~500 mcg two times per week once color is establishedcommunity
RouteSubQ (community reconstituted powder); some report mild flushing right after the shotcommunity

Reconstitution calculator

U-100 · 100u = 1 mL
mg
mL

= 200 units

Concentration
5 mg/mL
1 mg equals
20 units
Draw to
6 units
0501006u

Set the vial size and water to match your product — amounts vary by supplier. This is unit-conversion math, not medical advice or a dosing recommendation.

Pushing higher— going beyond the standard dosecommunity
This is a peptide where the community advice is explicitly to NOT chase a bigger dose. The reason isn't tolerance — it's that the dose-dependent downside is your existing freckles and moles getting darker and larger, which is both a cosmetic and a real dermatological concern. The repeated message is to start low (~250–300 mcg), titrate slowly, and stop at the lowest dose that holds your color. Nausea and flushing also scale with dose, but the mole/nevus darkening is the flag people take most seriously here — anyone with a lot of moles or a family melanoma history is told to get skin-checked, not to push the dose.

Side effects & cautions

The defining one is darkening and possible enlargement of existing moles and freckles — this is the side effect that matters most, because it can mask or mimic the kind of change a dermatologist watches for. Beyond that: mild flushing right after injection and dose-dependent nausea, both usually manageable by dosing lower. Note that nausea here is mild and pigment-pathway-adjacent, NOT the libido/appetite cluster — if someone is getting strong nausea, spontaneous erections or appetite loss, that points to MT-2, not MT-1. The honest unknown is long-term safety of chronic off-label use: the clinical safety record is for the EPP implant under medical supervision, not for years of self-injected research-grade powder.

Stacking

Not a stack component in any community protocol — it's run on its own for pigment. The only pairing people mention is behavioral, not pharmacological: still using real sun (or a minimal UV trigger) to actually express the tan, and watching their skin. It does NOT belong in the same conversation as MT-2 or PT-141 even though all three are melanocortin peptides; the receptor selectivity is the whole point of choosing MT-1.

Evidence & sources

Unusually, this peptide has genuine Phase-III RCT data and a regulatory approval — but for a rare light-sensitivity disease (EPP), as a 16 mg implant, not for cosmetic tanning. Two gaps the reader should hold: (1) the approved evidence is for EPP photoprotection, not for the microgram self-injection protocol the community runs; and (2) most "melanotan" sold online is actually MT-2, a different, non-selective, unapproved peptide — so the clinical data here often doesn't describe what someone is actually holding.

  • Langendonk JG et al. (2015)Human RCT
    Afamelanotide for erythropoietic protoporphyria (two Phase III RCTs)
    NEJM — pivotal randomized, placebo-controlled trialsPMID 26132941
  • Lim HW et al. (2015)Human RCT
    Afamelanotide + narrowband UV-B for vitiligo (randomized trial)
    JAMA Dermatology — combination RCTPMID 25230094
  • Biolcati G et al. (2015)Human study
    Long-term observational study of afamelanotide in 115 EPP patients
    British Journal of Dermatology — up to 8-year cohortPMID 25494545
  • Wensink D et al. (2020)Human study
    Afamelanotide outcomes in EPP in clinical practice
    JAMA Dermatology — real-world cohortPMID 32186677
  • U.S. FDA (2019)Regulatory
    Afamelanotide 16 mg implant approval for EPP photoprotection
    FDA NDA 210797 — first-in-class regulatory reviewNCT00979745

More in Sexual & pigment